The process is designed to take synthetic DNA, and via chemical synthesis, mRNA is produced from a series of methodologies.
Amsbio is offering a non-integrating strategy for reprogramming stem cell fate based on the administration of synthetic modified mRNA.
Following chemical synthesis of the DNA, dsDNA fragments are cloned in a plasmid which produces full sequencing documentation.
PCR amplification of the cloned inserts with the primers is then undertaken, purified using spin columns and the resultant DNA template characterised by capillary electrophoresis.
The subsequent RNA synthesis uses in vitro transcription methodologies and the resultant custom designed mRNA product is then purified and characterised ready for use.
